Compare Abbott Laboratories (ABT) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs SoundHound AI Inc — how do they compare? Abbott Laboratories trades at $95.41 (market cap $166.94B), while SoundHound AI Inc trades at $6.76 (market cap $2.88B). The key difference: Abbott Laboratories is far larger — about 58× SoundHound AI Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| ABT | SOUN | |
|---|---|---|
Market Cap | $166.94B | $2.88B |
Sector | Health | Technology |
52-Week High | $136.62 | $21.40 |
52-Week Low | $82.57 | $5.90 |
Enterprise Value | $193.69B | $2.67B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SoundHound AI (SOUN) trades at $6.96, up 6.26% on the day, with a bearish technical signal despite recent positive earnings beats. The company shows strong revenue growth in auto and IoT AI segments, up 88% year-over-year in Q1 2026, but faces profitability challenges with a net income margin of -91.84% and negative cash flow from operations. Analyst sentiment remains bullish with a $13.00 consensus price target, though the stock is down 37% year-to-date amid concerns over the LivePerson acquisition and high valuation multiples.
The outlook hinges on SOUN's ability to achieve profitability through scaling and cost synergies from acquisitions. Investment opportunities include market expansion in telecom and energy sectors, while risks involve persistent cash burn, competitive pressures, and execution risks in integrating LivePerson. The stock's high short interest could lead to volatility, but analyst optimism suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
